新・血栓止血血管学　凝固と炎症

出版社： 金芳堂
著者：
発行日： 2015-09-20
分野： 臨床医学：内科  >  血液
ISBN： 9784765316460
シリーズ： 新・血栓止血血管学
電子書籍版： 2015-09-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,600 円(税込)

購入する

商品紹介

本書は、最新の二光子顕微鏡による観察や細胞基盤型モデルにもとづく血栓の発生メカニズムなどをキャッチアップし、近年研究が著しく進んでいる血栓止血血管学の羅針盤となるべく編集された。また、血栓や止血についての理解は、血液の凝固因子の生化学的な作用だけでなく、血管の脈管形成や血管と神経の相互作用、血管と血液の物理的相互作用などの基礎的事実を踏まえてこそ進むと考える。そこで本書では、血小板と血管に着目した。血栓症と出血症の制圧のため、遺伝子から全身の脈管形成まで血管と血小板の動態を網羅した決定版である。

目次

  • 新・血栓止血血管学　凝固と炎症

    ―目次―

    1部　血管
    　 1．血管病の分子病態：AVMを含むオーバービュー
    　 2．造血管幹細胞を維持する骨髄の微小環境（ニッチ）
    　 3．脈管形成（血管／リンパ管発生）
    　 4．神経と血管のワイアリング
    　 5．血管と血流の相互作用
    　 6．プロテアーゼ活性化受容体PAR
    　 7．血管新生
    　 8．動脈の構造と動脈硬化の病理
    　 9．メタボリック症候群と血栓症
    　 10．静脈血栓塞栓症の予防と治療
    　 11．末梢動脈閉塞症

    2部　血小板
    　 12．血小板と血栓：オーバービュー
    　 13．血小板産生のメカニズム
    　 14．血小板の超微細形態
    　 15．血小板機能と血流
    　 16．血小板反応とそのシグナル伝達機構
    　 17. 血栓形成制御とシミュレーション理論
    　 18. めでみる血栓形成過程：二光子顕微鏡の生体への応用
    　 19．先天性血小板異常症の今（先天性巨大血小板症を含む）
    　 20．ScramblaseとScott症候群
    　 21．von Willebrand病
    　 22．ADAMTS13
    　 23．TTPとaHUS
    　 24．ヘパリン起因性血小板減少症
    　 25．免疫性血小板減少症
    　 26．感染症と血小板
    　 27．白血球・血小板複合体（NETs）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1部 凝固反応

P.7 掲載の参考文献
1) Becker RC. Cell-based models of coagulation : a paradigm in evolution. J Thromb Thrombolysis 2005 ; 20 (1) : 65-68.
PubMed
2) Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003 ; 1 (7) : 1504-1514.
PubMed
3) Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH. Phosphatidylethanolamine augments factor VIIa-tissue factor activity : enhancement of sensitivity to phosphatidylserine. Biochemistry 1995 ; 34 (43) : 13988-13993.
PubMed
4) Owens AP, Mackman N. Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque. Thromb Res 2012 ; 129 (Suppl) : S30-S33.
 
5) Jasuja R, Passam FH, Kennedy DR, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 2012 ; 122 (6) : 2104-2013
 
6) Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007 ; 27 (8) : 1687-1693.
PubMed
7) Rautou PE, Vion AC, Amabile N, et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011 ; 109 (5) : 593-606.
PubMed
8) Tushuizen ME, Diamant M, Sturk A, et al. Cell-Derived Microparticles in the Pathogenesis of Cardiovascular Disease : Friend or Foe? Arterioscler Thromb Vasc Biol 2010 ; 31 (1) : 4-9.
PubMed
9) Crawley JTB, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2008 ; 28 (2) : 233-242.
PubMed
10) Roberts HR, Monroe DM, Oliver JA, et al. Newer concepts of blood coagulation. Haemophilia 1998 ; 4 (4) : 331-334.
PubMed
11) Nakagaki T, Foster DC, Berkner KL, et al. Initiation of the extrinsic pathway of blood coagulation : evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 1991 ; 30 (45) : 10819-10824.
PubMed
12) Pedersen AH, Lund-Hansen T, Bisgaard-Frantzen H, et al. Autoactivation of human recombinant coagulation factor VII. Biochemistry 1989 ; 28 (24) : 9331-9336.
PubMed
13) Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003 ; 16 (1-2) : 17-20.
 
14) Van Dieijen G, Tans G, Rosing J, et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981 ; 256 (7) : 3433-3442.
PubMed
15) Jennewein C, Tran N, Paulus P, et al. Novel aspects of fibrin (ogen) fragments during inflammation. Mol Med 2011 ; 17 (5-6) : 568-573.
 
16) Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) -how does thrombin regulate fibrinolysis? Ann Med 2006 ; 38 (6) : 378-388.
PubMed
P.18 掲載の参考文献
1) Fish RJ, Neerman-Arbez M. Fibrinogen gene regulation. Thromb Haemost 2012 ; 108 : 419-426.
PubMed
2) Ariens RA. Fibrin (ogen) and thrombotic disease. J Thromb Haemost 2013 ; 11 (Suppl 1) : 294-305.
 
3) Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood 2013 ; 121 : 1712-1719.
PubMed
4) Protopopova AD, Barinov NA, Zavyalova EG, et al. Visualization of fibrinogen α C regions and their arrangement during fibrin network formation by highresolution AFM. J Thromb Haemost 2015 ; 13 : 570-579.
 
5) Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Med Chem 2008 ; 6 : 206-211.
PubMed
6) de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders : an update. Semin Thromb Hemost 2013 ; 39 : 585-595.
PubMed
7) Bornikova L, Peyvandi F, Allen G, et al. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011 ; 9 : 1687-1704.
PubMed
8) Weisel JW. Biophysics. Enigmas of blood clot elasticity. Science 2008 ; 320 : 456-457.
PubMed
9) Liu W, Jawerth LM, Sparks EA, et al. Fibrin fibers have extraordinary extensibility and elasticity. Science 2006 ; 313 : 634.
PubMed
10) Yermolenko IS, Lishko VK, Ugarova TP, et al. Highresolution visualization of fibrinogen molecules and fibrin fibers with atomic force microscopy. Biomacromolecules. 2011 ; 12 : 370-379.
PubMed
11) Tsurupa G, Pechik I, Litvinov RI, et al. On the mechanism of αC polymer formation in fibrin. Biochemistry 2012 ; 51 : 2526-2538.
 
12) Litvinov RI, Yakovlev S, Tsurupa G, et al. Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other. Biochemistry 2007 ; 46 : 9133-9142.
PubMed
13) Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012 ; 95 : 362-370.
PubMed
14) Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001 ; 86 : 57-65.
PubMed
15) Kohler HP, Ichinose A, Seitz R, et al. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011 ; 9 : 1404-1406.
PubMed
16) Kaetsu H, Hashiguchi T, Foster D, et al. Expression and release of the a and b subunits for human coagulation factor XIII in baby hamster kidney (BHK) cells. J Biochem. 1996 ; 119 : 961-969.
 
17) Smith KA, Pease RJ, Avery CA, et al. The activation peptide cleft exposed by thrombin cleavage of FXIII-A (2) contains a recognition site for the fibrinogen α chain. Blood. 2013 ; 121 : 2117-2126.
 
18) Souri M, Koseki-Kuno S, Takeda N, et al. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knockout mice. Int J Hematol. 2008 ; 87 : 60-68.
PubMed
19) Souri M, Osaki T, Ichinose A. The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking. J Biol Chem 2015 ; 290 : 12027-12039.
PubMed
20) Smith KA, Adamson PJ, Pease RJ, et al. Interactions between factor XIII and the alphaC region of fibrinogen. Blood 2011 ; 117 : 3460-3468.
PubMed
21) Iwata H, Kitano T, Umetsu K, et al. Distinct C-terminus of the B subunit of factor XIII in a population-associated major phenotype : the first case of complete allele-specific alternative splicing products in the coagulation and fibrinolytic systems. J Thromb Haemost. 2009 ; 7 : 1084-1091.
 
22) Mezei ZA, Bereczky Z, Katona E, et al. Factor XIII B subunit polymorphisms and the risk of coronary artery disease. Int J Mol Sci 2015 ; 16 : 1143-1159.
PubMed
23) Komanasin N, Catto AJ, Futers TS, et al. A novel polymorphism in the factor XIII B-subunit (His95Arg) : relationship to subunit dissociation and venous thrombosis. J Thromb Haemost 2005 ; 3 : 2487-2496
 
24) Wada H, Souri M, Matsumoto R, et al. Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency. Thromb Haemost 2013 ; 109 : 661-668.
 
25) Zhang WG, Souri M, Ichinose A. Proteosomal degradation of naturally recurring R260C missense and exon-IV deletion mutants of factor XIII A-subunit expressed in mammalian cells. Haemophilia 2013 ; 19 : 415-419.
 
26) Arokszallasi A, Kerenyi A, Katona E, et al. The use of recombinant factor XIII in a major bleeding episode of a patient with congenital factor XIII deficiency--the first experience. Haemophilia. 2015 ; 21 : e118-e121.
 
27) Inbal A, Oldenburg J, Carcao M, et al. Recombinant factor XIII : a safe and novel treatment for congenital factor XIII deficiency. Blood 2012 ; 119 : 5111-5117.
PubMed
28) Kitchens CS, Newcomb TF. Factor XIII. Medicine (Baltimore). 1979 ; 58 : 413-429.
PubMed
29) Board PG, Losowsky MS, Miloszewski KJ. Factor XIII : inherited and acquired deficiency. Blood Rev. 1993 ; 7 : 229-242.
PubMed
30) Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia. 2008 ; 14 : 1190-1200.
PubMed
31) Stieler M, Weber J, Hils M, et al. Structure of active coagulation factor XIII triggered by calcium binding : basis for the design of next-generation anticoagulants. Angew Chem Int Ed Engl 2013 ; 52 : 11930-11934.
PubMed
P.27 掲載の参考文献
1) Fair DS, Bahnak BR. Human hepatoma cells secret single chain factor X, prothrombin and antithrombin III. Blood 1984 ; 64 : 194-204.
 
2) Leytus SP, Foster DC, Kurachi K, et al. Gene for human factor X : a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 1986 ; 25 : 5098-5102.
PubMed
3) Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002 ; 22 : 1381-1389.
PubMed
4) Kisiel W, Hermodson MA, Davie EW. Factor X activating enzyme from Russell's viper venom : isolation and characterization. Biochemistry 1976 ; 15 : 4901-4906.
PubMed
5) Altieri DC, Morrissey JH, Edgington TS. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation : an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci U S A. 1988 ; 85 : 7462-7466.
PubMed
6) Mann KG, Krishnaszamy S, Lawson JH. Surfacedependent hemostasis. Semin Hematol 1992 ; 29 : 213-226.
 
7) Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost. 2003 ; 1 : 1495-1503.
PubMed
8) Manegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost 2009 ; 35 : 407-415.
 
9) Girolami A, Cosi E, Sambado L, et al. Complex history of the discovery and characterization of congenital factor X deficiency. Semin Thromb Hemost 2015 ; 41 : 359-365.
PubMed
10) Telfer TP, Denson KW, Wright DR. A 'new' coagulation defect. Brit J Haemat 1956 ; 2 : 308-316.
PubMed
11) Hougie C, Barrow EM, Graham JB. Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called 'stable factor' (SPCA, proconvertin, factor VII) deficiency. J Clin Invest 1957 ; 36 : 485-496.
PubMed
12) http://www.biobase-international.com/product/hgmd
 
13) Dewerchin M, Liang Z, Moons L, et al. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice. Thromb Haemost 2000 ; 83 : 185-190.
PubMed
14) Greipp PR, Kyle RA, Bowie EJ. Factor X deficiency in amyroidosis : a critical review. Am J Hematol 1981 ; 11 : 443-450.
PubMed
15) Choufani EB, Sanchorawala VS, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyroidosis : incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001 ; 97 : 1885-1887.
 
16) Lee G, Duan-Porter W, Metjian AD. Acquired, nonamyloid related factor X deficiency : review of the literature. Haemophilia 2012 ; 18 : 655-663.
PubMed
17) Degen SJ, Davie EW. Nucleotide sequence of the gene for human prothrombin. Biochemistry 1987 ; 26 : 6165-6177.
PubMed
18) Krishnaswamy S. The transition of prothrombin to thrombin. J Thromb Haemost 2013 ; Suppl 1 : 265-276.
 
19) Yamada D, Sekiya F, Morita T. Isolation and characterization of carinactivase, a novel prothrombin activator in Echis carinatus venom with a unique catalytic mechanism. J Biol Chem 1996 ; 271 : 5200-5207.
PubMed
20) Friedrich R, Panizzi P, Fuentes-Prior P, et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 2003 ; 425 : 535-539.
PubMed
21) Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991 ; 64 : 1057-1068.
PubMed
22) Lancellotti S, De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost 2009 ; 35 : 367-381.
PubMed
23) Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency : an update. Semin Thromb Hemost 2013 ; 39 : 596-606.
PubMed
24) Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3' -untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996 ; 88 : 3698-703.
 
25) Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012 ; 366 : 2390-2396.
PubMed
26) Morishita E, Saito M, Kumabashiri I, Asakura H, Matsuda T, Yamaguchi K : Prothrombin Himi : A compound heterozygote for two dysfunctional prothrombin molecules (Met-337 → Thr and Arg-388 → His). Blood 1992 ; 80 : 2275-2280.
 
27) Xue J, Wu Q, Westfield LA, et al. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci USA 1998 ; 95 : 7603-7607.
 
28) Sun WY, Witte DP, Degen JL, et al, Burkart MC, Holmback K, Xiao Q, Bugge TH, Degen SJ. Prothrom bin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci USA 1998 ; 95 : 7597-7602.
 
29) Bajaj SP, Rapaport SI, Barclay S, et al. Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin : mechanism and management. Blood 1985 ; 65 : 1538-1543.
PubMed
30) Paschal RD, Neff AT. Resolution of Hypoprothrombinemia-Lupus Anticoagulant Syndrome (HLAS) after multidrug therapy with rituximab : a case report and review of the literature. Haemophilia 2013 ; 19 : e62-e65.
 
P.33 掲載の参考文献
1) Rosendaal F. Venous thrombosis : a multicausal disease. Lancet 1999 ; 353 : 1167-1173.
PubMed
2) Kimura R, Honda S, Kawasaki T, et al. Protein S K196E mutation as a genetic risk for deep vein thrombosis in Japanese patients. Blood 2006 ; 107 : 1737-1738.
PubMed
3) Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012 ; 366 : 2390-2396.
PubMed
4) Matsushita T, Saito H, Kojima T. Thrombosis from a prothrombin mutation conveying antithrombin resistance. (The authors reply) N Engl J Med 2012 ; 367 : 1069-1070.
 
5) Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965 ; 13 : 516. (Abstract)
 
6) Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981 ; 68 : 1370-1373.
 
7) Comp P, Esmon C : Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984 ; 311 : 1525-1528.
PubMed
8) Miyata T, Sato Y, Ishikawa J, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res 2009 ; 124 : 14-18.
PubMed
9) Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994 ; 369 : 64-67.
PubMed
10) Poort SR, Rosendaal FR, Reitsma PH, et al. Aq common genetic variation in the 3' -untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996 ; 88 : 3698-3703.
 
11) Simioni P, Tormene D, Tognin G, et al. X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua). N Engl J Med 2009 ; 361 : 1671-1675.
PubMed
12) 酒井道生, 浦野元, 飯沼麻美, 他. 乳児発症例を含む血栓症多発の1家系. J UOEH (産業医科大学雑誌) 2001 ; 23 : 297-305.
 
13) ten Kate M, He C, van Schouwenburg IM, et al. A genome wide linkage scan for thrombosis susceptibility genes identifies a novel prothrombin mutation. XXII Congress of ISTH, Boston. 2009 ; OC-WE-098 (Abstract).
 
14) Li W, Johnson DJ, Esmon CT, et al. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 2004 ; 11 : 857-862.
PubMed
15) Murata M, Takagi A, Suzuki A, et al. Development of a new laboratory test to evaluate antithrombin resistance in plasma. Thromb Res 2014 ; 133 : 293-298.
PubMed
16) 村田萌, 高木明, 岸本磨由子, 他 : 原因不明であった静脈血栓塞栓症にみられたアンチトロンビン抵抗性を示す本邦2家系目のプロトロンビン異常症. 第33回日本臨床検査医学会東海・北陸支部例会. 2014 ; 抄録集.
 
17) Djordjevic V, Kovac M, Miljic P, et al. A novel prothrombin mutation in two families with prominent thrombophilia--the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost 2013 ; 11 : 1936-1939.
 
18) Sivasundar S, Oommen AT, Prakash O, et al : Molecular defect of 'Prothrombin Amrita' : substitution of arginine by glutamine (Arg553 to Gln) near the Na (+) binding loop of prothrombin. Blood Cells Mol Dis 2013 ; 50 : 182-183.
PubMed
P.40 掲載の参考文献
1) 高宮脩. 第VII因子の基礎と臨床. In : 一瀬白帝 (編). 図説 血栓・止血・血管学. 中外医学社, 東京, 2005 : p313-327.
 
2) Hoffman M, Meng ZH, Roberts HR, et al. Rethinking the Coagulation Cascade 日本血栓止血学会誌 2005 ; 16 : 70-81.
 
3) Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996 7 ; 380 : 41-46.
 
4) Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation. Thromb Haemost 1997 ; 78 : 401-405.
PubMed
5) Eigenbrot C. Structure, function, and activation of coagulation Factor VII. Curr Protein Pept Sci 2002 ; 3 : 287-299.
PubMed
6) 東昌市. 血液凝固因子と組織因子の分子間相互作用-特にVIIA因子触媒活性の増強機構について-, 日本血栓止血学会誌 1999 ; 10 : 12-21.
 
7) Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa : effects of calcium, phospholipids, and tissue factor. Biochemistry. 1990 ; 29 : 9418-9425.
 
8) Neuenschwander PF, Branam DE, Morrissey JH. Importance of substrate composition, pH and other variables on tissue factor enhancement of factor VIIa accceleration of factor VIIa activity. J Biol Chem 1996 ; 271 : 26569-26574.
 
9) Romisch J. Factor VII activating protease (FSAP) : A novel protease in hemostasis. Biol Chem 2002 ; 383 : 1119-1124.
PubMed
10) Stavenuiter F, Dienava-Verdoold I, Boon-Spijker MG, et al. Factor seven activating protease (FSAP) : does it activate factor VII? J Thromb Haemost 2012 ; 10 : 859-866.
PubMed
11) Scarabin PY, Vissac AM, Kirzin JM, et al. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996 ; 16 : 1170-1176.
PubMed
12) Hunault M, Arbini AA, Lopaciuk S, et al. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol 1997 ; 17 : 2825-2829.
PubMed
13) Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994 ; 71 : 719-722.
PubMed
14) http://c.ymcdn.com/sites/www.isth.org/resource/resmgr/publications/fvii_mutations-2011.pdf
 
15) http://www.umd.be/F7/W_F7/index.html
 
16) 高宮脩. 日本人の先天性第VII 因子欠乏・異常症の遺伝子変異, 日本血栓止血学会誌 2008 ; 19 : 64-76.
 
17) Takamiya O, Ishikawa S, Ohnuma O, et al. Japanese collaborative study to assess inter-laboratory variation in factor VII activity assays. J Thromb Haemost 2007 ; 5 : 1686-1692.
PubMed
18) 高宮脩, 沖本由理. 先天性第VII因子欠乏症, 日本血栓止血学会誌 2001 ; 12 : 320-327.
 
19) Aguilar C, Lucia JF, Hernandez P.A case of an inhibitor autoantibody to coagulation factor VII. Haemophilia 2003 ; 9 : 119-120.
 
20) 桑原光弘. Factor VIIa製剤の過去・現在・未来, 日本血栓止血学会誌 2014 ; 25 : 475-481.
 
21) Baumann Kreuziger LM, Morton CT, Reding MT. Is prophylaxis required for delivery in women with factor VII deficiency? Haemophilia 2013 ; 19 : 827-832.
 
22) Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor : a circulating, soluble, thrombogenic protein. Nat Med 2003 ; 9 : 458-462.
PubMed
23) Sluka SH, Akhmedov A, Vogel J, et al. Alternatively spliced tissue factor is not sufficient for embryonic development. PLoS One 2014 ; 9 : e97793.
 
24) Kocaturk B, Van den Berg YW, Tieken C, et al. Alternatively spliced tissue factor promotes breast cancer growth in a beta1 integrin-dependent manner. Proc Natl Acad Sci U S A. 2013 ; 110 : 11517-11522.
 
25) Ott I, Fischer EG, Miyagi Y, et al. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol. 1998 ; 140 : 1241-1253.
PubMed
26) 武谷浩之. 組織因子による細胞機能の修飾. 血管医学 2005-6 ; 6 : 9-17.
 
27) Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature. 1996 ; 383 : 73-75.
PubMed
28) Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A. 1996 ; 93 : 6258-6263.
PubMed
29) Parry GC, Mackman N. Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain. J Clin Invest. 2000 ; 105 : 1547-1554.
 
30) 武谷浩之, 鈴木宏治. 細胞性血液凝固の制御調節機構. 生化学 1998 ; 70 : 1436-1441.
 
31) Brunner JD, Lim NK, Schenck S, et al. X-ray structure of a calcium-activated TMEM16 lipid scramblase. Nature 2014 ; 516 : 207-212.
PubMed
32) Kothari H, Pendurthi UR, Rao LV. Analysis of tissue factor expression in various cell model systems : cryptic vs. active. J Thromb Haemost 2013 ; 11 : 1353-1363.
PubMed
33) Kothari H, Nayak RC, Rao LV, et al. Cystine 186-cystine 209 disulfide bond is not essential for the procoagulant activity of tissue factor or for its deencryption. Blood 2010 ; 115 : 4273-4283.
PubMed
34) Deguchi H, Takeya H, Urano H, et al. Adenosine regulates tissue factor expression on endothelial cells. Thromb Res 1998 ; 91 : 57-64.
PubMed
35) Takeya H, Gabazza EC, Aoki S, et al Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood 2003 ; 102 : 1693-1700.
PubMed
36) Takeya H, Suzuki K. Lipid mediators and tissue factor expression. In : Tanaka K, Davie EW (eds.) Recent Advances in Thrombosis and Hemostasis 2008. Tokyo : Springer ; 2008 : 133-146.
 
37) Aras O, Shet A, Bach RR, et al. Induction of microparticle-and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004 ; 103 : 4545-4553.
PubMed
38) Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood 2014 ; 123 : 2605-2613.
PubMed
39) Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor : a study in rhesus monkeys. Lancet 2003 ; 362 : 1953-1958.
PubMed
40) Owens AP, 3rd, Passam FH, Antoniak S, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012 ; 122 : 558-568.
PubMed
41) Pyo RT, Sato Y, Mackman N, et al. Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration. Thromb Haemost 2004 ; 92 : 451-458.
PubMed
42) Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013 ; 122 : 2011-2018.
PubMed
43) Whelihan MF, Lim MY, Key NS. Red blood cells and thrombin generation in sickle cell disease. Thromb Res 2014 ; 133 Suppl 1 : S52-S53.
 
P.52 掲載の参考文献
1) Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984 ; 312 : 342-347.
PubMed
2) Lesley A. Everett, Audrey C, et al. Murine coagulation factor VIII is synthesized in endothelial cells. Blood 2014 ; 123 : 3697-3705.
 
3) Fahs SA, Hille MT, Shi Q, et al. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 2014 ; 123 : 3706-3713.
 
4) Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999 ; 402 : 439-442.
PubMed
5) Shen BW, Spiegel PC, Chang CH, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008 ; 111 : 1240-1247.
PubMed
6) Adams TE, Hochin MF, Mann KG, et al. The crystal structure of activated protein C-inactivated bovine factor Va : Implications for cofactor function. Proc Natl Acad Sci USA 2004 ; 101 : 8918-8923.
 
7) Wakabayashi H, Koszelak ME, Mastri M, et al. Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. Biochemistry 2001 ; 40 : 10293-10300.
PubMed
8) Wakabayashi H, Freas J, Zhou Q, et al. Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity. J Biol Chem 2004 ; 279 : 12677-12684.
PubMed
9) Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004 ; 18 : 1-15.
PubMed
10) Nogami K, Zhou Q, Myles T, et al. Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain. J Biol Chem 2005 ; 280 : 18476-18487.
 
11) Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000 ; 275 : 25774-25780.
PubMed
12) Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999 ; 274 : 31000-31007.
PubMed
13) Nogami K, Lapan KA, Zhou Q, et al. Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain. J Biol Chem 2004 ; 279 : 15763-15771.
 
14) Nogami K, Saenko EL, Takeyama M, et al. Identification of a thrombin-interactive site within the FVIII A2 domain that is responsible for the cleavage at Arg372. Br J Haematol 2008 ; 140 : 433-443.
PubMed
15) Soeda T, Nogami K, Matsumoto T, et al. Mechanisms of factor VIIa-catalyzed activation of factor VIII. J Thromb Haemost. 2010 ; 11 : 2494-2503.
PubMed
16) Nogami K, Wakabayashi H, Fay PJ. Mechanisms of factor Xa-catalyzed cleavage of the factor VIIIa A1 subunit resulting in cofactor inactivation. J Biol Chem. 2003 ; 278 : 16502-16509.
PubMed
17) Nogami K, Shima M, Matsumoto T, et al. Mechanisms of plasmin-catalyzed inactivation of factor VIII : a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation. J Biol Chem 2007 ; 282 : 5287-5295.
PubMed
18) Takeyama M, Nogami K, Saenko EL, et al. Protein S down-regulates factor Xase activity independent of activated protein C : specific binding of factor VIII (a) to protein S inhibits interactions with factor IXa. Br J Haematol. 2008 ; 143 : 409-420.
 
19) Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood. 2000 ; 95 : 156-163.
 
20) Soeda T, Nogami K, Nishiya K, et al. The factor VIIIa C2 domain (residues 2228-2240) interacts with the factor IXa Gla domain in the factor Xase complex. J Biol Chem 2009 ; 284 : 3379-3388.
PubMed
21) Takeyama M, Wakabayashi H, Fay PJ. Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase. Biochemistry. 2012 ; 51 : 820-828.
 
22) Bovenschen N, van Stempvoort G, Voorberg J, et al. Proteolytic cleavage of factor VIII heavy chain is required to expose the binding-site for low-density lipoprotein receptor-related protein within the A2 domain. J Thromb Haemost 2008 ; 4 : 1487-1493.
 
23) Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A : results of an international consortium study. Blood 1995 ; 86 : 2206-2212.
 
24) Shima M, Ware J, Yoshioka A, et al. An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule. Blood 1989 ; 74 : 1612-1617.
 
25) Nogami K, Zhou Q, Wakabayashi H, et al. Thrombincatalyzed activation of factor VIII with His substituted for Arg372 at the P1 site. Blood 2005 ; 105 : 4362-4368.
PubMed
26) Liu ML, Shen BW, Nakaya S, et al. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 2000 ; 96 : 979-987.
 
27) D'Oiron R, Lavergne JM, Lavend' homme R, et al. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood 2004 ; 103 : 155-157.
 
28) Aly AM, Higuchi M, Kasper CK, et al. Hemophilia A due to mutations that create new N-glycosylation sites. Proc Natl Acad Sci USA 1992 ; 89 : 4933-4937.
 
29) Pipe SW, Kaufman RJ. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J Biol Chem 1996 ; 271 : 25671-25676.
PubMed
30) Pipe SW, Eickhorst AN, McKinley SH, et al. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation : evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999 ; 93 : 176-183.
PubMed
31) Jenkins PV, Freas J, Schmidt KM, et al. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex. Blood 2002 ; 100 : 501-508.
PubMed
32) Yada K, Nogami K. Recent advance in hemophilia therapy (1) : long-acting agents and antibody drugs. Rinsho Ketsueki 2014 ; 55 : 893-898.
PubMed
33) Rosing J, Tans G. Coagulation factor V : an old star shines again. Thromb Haemost 1997 ; 78 : 427-33. Review.
PubMed
34) Duckers C, Simioni P, Spiezia L, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008 ; 112 : 3615-3623.
PubMed
35) Duckers C, Simioni P, Spiezia L, et al. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood 2010 ; 115 ; 879-886.
PubMed
36) Bos MH, Camire RM : A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem 2012 ; 287 : 26342-26351.
 
37) Vincent LM, Tran S, Livaja R, et al. Coagulation factor V (A2440G) causes east Texas bleeding disorder via TFPI α . J Clin Invest 2013 ; 123 : 3777-3787.
 
38) Wood JP, Bunce MW, Maroney SA, et al. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci USA 2013 ; 110 : 17838-17843.
PubMed
39) Nichols WC, Seligsohn U, Zivelin A, et al. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 1998 ; 93 : 61-70.
PubMed
40) Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C.J Biol Chem 1994 ; 269 : 31869-31880.
PubMed
41) Yegneswaran S, Wood GM, Esmon CT, et al. Protein S alters the active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study of topography. J Biol Chem 1997 ; 272 : 250313-250321.
 
42) Yegneswaran S, Smirnov MD, Safa O, et al. Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study. J Biol Chem 1999 ; 274 : 5462-5468.
PubMed
43) Lu D, Kalafatis M, Mann KG, et al. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996 ; 87 : 4708-4717.
PubMed
44) Thorelli E, Kaufman RJ, Dahlback B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998 ; 273 : 16140-16145.
 
45) van de Poel RH, Meijers JC, Bouma BN. C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost 2001 ; 85 : 761-765.
 
46) Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C : prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993 ; 90 : 1004-1008.
PubMed
47) Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994 ; 369 : 64-67.
PubMed
48) Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C : Leiden Thrombophilia Study. Lancet 1993 ; 342 : 1503-1506.
PubMed
49) Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995 ; 346 : 1133-1134.
PubMed
50) Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995 ; 85 : 1504-1508.
PubMed
51) van Stralen KJ, Doggen CJ, Bezemer ID, et al. Mechanisms of the factor V Leiden paradox. Arterioscler Thromb Vasc Biol 2008 ; 28 : 1872-1877.
PubMed
52) Williamson D, Brown K, Luddington R, et al. Factor V Cambridge : a new mutation (Arg306-->Thr) associated with resistance to activated protein C. Blood 1998 ; 91 : 1140-1144.
PubMed
53) Chan WP, Lee CK, Kwong YL, et al. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998 ; 91 : 1135-1139.
 
54) Mumford AD, McVey JH, Morse CV, et al. Factor V I359T : a novel mutation associated with thrombosis and resistance to activated protein C. Br J Haematol 2003 ; 123 : 496-501.
PubMed
55) Cai H, Hua B, Fan L, et al. A novel mutation (g2172--&gt ; c) in the factor V gene in a Chinese family with hereditary activated protein C resistance.Thromb Res 2010 ; 125 : 545-548.
 
56) 山崎鶴夫 : Factor Vを見直そう : Factor V R2 haplotypeと血栓症 : 血栓止血誌 2003 ; 14 : 310-315.
 
57) Nogami K, Shinozawa K, Ogiwara K, et al. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden. Blood 2014 ; 123 : 2420-2428.
PubMed
58) Maruyama K, Morishita E, Sekiya A, et al. A novel factor V mutation which causes deep vein thrombosis. IJH annual meeting S-2-115, 2012.
 
59) 荻原建一, 野上恵嗣. Tissue factor pathway inhibitor (TFPI) の新知見と臨床応用 : 血栓止血誌 2014 ; 25 : 11-22.
 
60) 篠澤圭子, 野上恵嗣. Factor Vがいよいよ面白くなってきた : 血栓症をおこしたFVNARA変異とAPCレジスタンス. 血栓止血誌 2014 ; 25 : 482-493.
 
P.62 掲載の参考文献
1) Yoshitake S, Schach BG, Foster DC, et al. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985 ; 24 : 3736-3750.
PubMed
2) Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 1982 ; 79 : 6461-6464.
PubMed
3) Kurachi S, Hitomi Y, Furukawa M, et al. Role of intron 1 in expression of the human factor IX gene. J Biol Chem 1995 ; 270 : 5276-5281.
 
4) Thompson AR. Structure, function, and molecular defects of factor IX. Blood 1986 ; 67 : 565-572.
PubMed
5) Brandstetter H, Bauer M, Huber R et al. X-Ray structure of clotting factor IXa. Active site and module structure related to Xase activity and hemophilia B. Proc Nat Acad Sci USA 1995 ; 92 : 9796-9800.
PubMed
6) Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991 ; 266 : 11317-11327.
PubMed
7) van Dieijen G, Tans G, Rosing J, et al. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981 ; 256 : 3433-3442.
PubMed
8) Wu SM, Cheung WF, Frazier D, et al. Cloning and expression of the cDNA for human gamma-flutamyl carboxylase. Science 1991 ; 254 : 1634-1636.
 
9) Rabiet MJ, Jorgensen MJ, Furie B, et al. Effect of propeptide mutations on post-translational processing of factor IX. J Biol Chem 1987 ; 262 : 14895-14898.
PubMed
10) Bajaj SP. Cooperative Ca2+ binding to human factor IX. Effects of Ca2+ on the kinetic parameters of the activation of factoe IX by factor Xia. J Biol Chem 1982 ; 257 : 4127-4132.
 
11) Zong D, Bajaj MS, Schmidt AE, et al. The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor. J Biol Chem 2002 ; 277 : 3622-3631.
 
12) Lenting PJ, Christophe OD, Maat H, et al. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. J Biol Chem 1996 ; 271 : 253332-25337.
 
13) Schmidt AE, Bajaj SP. Structure-function relations in factor IX and factor IXa. Trends Cardiovasc Med 2003 ; 13 : 39-45.
 
14) Celie PH, Van Stempvoort G, Fribourg C, et al. The connecting segment between both epidermal growth factor-like domains in blood coagulation factor IX contributes to stimulation by factor VIIIa and its isolated A2 domain. J Biol Chem. 2002 ; 277 : 20214-20220.
PubMed
15) Atoda H, Yokota E, Morita T. Characterization of a monoclonal antibody B1 that recognizes phosphorylated Sr-158 in the activation peptide region of human coagulation factor IX J Biol Chem 2006 ; 281 : 9314-9320.
 
16) van Dieijen G, Tans G, Rosing J, et al. The role if phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981 ; 256 : 3433-3442.
PubMed
17) Hopfner KP, Lang A, Karcher A, et al. Coagulation factor IXa : the relaxed conformation of Tyr99 blocks substarate binding. Structure 1999 ; 7 : 989-996.
 
18) Kolkman JA, Merters K. Insertion loop 256-258 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII. Biochemistry 2000 ; 39 : 7398-7405.
 
19) Aggeler PM, Whute SG, Glendening MB, et al. Plasma thromboplastin (PTC) deficiency ; a new disease ressenbling hemophilia. Proc Soc Exp Biol Med. 1952 ; 79 : 692-694.
 
20) Rogaev EI, Grigorenko AP, Moliaka YK, et al. Genomic identification in the historical case of the Nicholas II royal family. Proc Natl Acad Sci USA. 2009 ; 106 : 5258-5263.
PubMed
21) 血液凝固異常症全国調査運営委員会. 血液凝固異常症全国調査平成26年度報告書 (厚生労働省委託事業). 公益財団法人エイズ予防財団. 2015.
 
22) Rallapalli PM, Kemball-Cook G, Tuddenham EG, et al. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost 2013 ; 11 : 1329-1340.
PubMed
23) Crossley M, Ludwig M, Stowell KM, et al. Recovery from hemophilia B Leiden : an androgen-responsive element in the factor IX promoter. 1992 ; 257 : 377-379.
 
24) Ware J, Diuguid DL, Liebman HA, et al. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties. J Biol Chem 1989 ; 264 : 11401-11406.
PubMed
25) Koh A, Suzuki T, Shinozawa K, et al.Four novel missense mutations in factor IX gene were identified as causes of hemophilia B. Jpn J Hemost Thromb 2007 ; 18 : 166-174.
 
26) Lozier JN, Monrose DM, Stanfield-Oakley S, et al. Factor IX New London : substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood 1990 ; 75 : 1097-1104.
 
27) Noyes CM, Griffith MJ, Roberts HR, et al. Identification of the molecular defect in factor IX Chapel Hill : substitution of histidine for arginine at position 145. Proc Natl Acad Sci USA 1983 ; 80 : 4200-4202.
PubMed
28) Whiite G, Shapiro A, Ragni M, et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998 ; 35 : 33-38.
 
29) Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010 ; 115 : 2057-2064.
PubMed
30) Powell JS, Pasi KJ, Ragni MV, et al. B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013 ; 369 : 2313-2323.
PubMed
31) Negrier C, KnobeK, Tiede A, et al. Enhanced pharmacokinetic prpperties of a glycolPEGylated recombinant factor IX : a first human dose trial in patients with hemophilia B. Blood 2011 ; 118 : 2695-2701.
 
32) Santagostino E, negrier C, Klamoroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012 ; 120 : 2405-24011.
 
33) Nathwani AC, Reiss UM, Tuddenham EG, et al. Longterm safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014 ; 371 : 1994-2004.
PubMed
P.70 掲載の参考文献
1) Morrissey JH, Choi SH, Smith SA. Polyphosphate : an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012 ; 119 : 5972-5979.
PubMed
2) Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014 ; 111 : 570-574.
PubMed
3) Smith SA, Morrissey JH. Polyphosphate : a new player in the field of hemostasis. Curr Opin Hematol. 2014 ; 21 : 388-394.
PubMed
4) Moreno SN, Docampo R. Polyphosphate and its diverse functions in host cells and pathogens. PLoS Pathog. 2013 ; 9 : e1003230.
PubMed
5) 西村仁, 平井秀憲, 宮田敏行. 凝固XI因子の構造と機能. 血栓止血誌. 2012 ; 23 : 594-598.
 
6) 宮田敏行, 喜多俊行 : VI. 凝固線溶系 3. 内因系凝固反応と血栓症. In : 高久 史麿, 小澤 敬也, 坂田洋一, 他編. Annual Review 血液 2012. 東京 : 中外医薬社, 2012 : 236-244.
 
7) Rao NN, Gomez-Garcia MR, Kornberg A. Inorganic polyphosphate : essential for growth and survival. Annu Rev Biochem 2009 ; 78 : 605-647.
PubMed
8) Lorenz B, Schroder HC. Mammalian intestinal alkaline phosphatase acts as highly active exopolyphosphatase. Biochim Biophys Acta 2001 ; 1547 : 254-261.
PubMed
9) Smith SA, Mutch NJ, Baskar D, et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 2006 ; 103 : 903-908.
PubMed
10) Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow : report of two cases with histochemical studies. Blood 1959 ; 14 : 162-169.
PubMed
11) Ruiz FA, Lea CR, Oldfield E, et al. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004 ; 279 : 44250-44257.
PubMed
12) Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009 ; 139 : 1143-1156.
PubMed
13) Colhoun HM, Zito F, Norman Chan N, et al. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 2002 ; 163 : 363-369.
PubMed
14) Grundt H, Nilsen DW, Hetland O, et al. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 2004 ; 147 : 260-266.
PubMed
15) Muller F, Renne T. Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 2008 ; 15 : 516-521.
PubMed
16) Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007 ; 27 : 2507-2513.
PubMed
17) Kalter ES, van Dijk WC, Timmerman A, et al. Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis 1983 ; 148 : 682-691.
PubMed
18) Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010 ; 116 : 4353-4359.
PubMed
19) Engel R, Brain CM, Paget J, et al. Single-chain factor XII exhibits activity when complexed to polyphosphate. J Thromb Haemost 2014 ; 12 : 1513-1522.
PubMed
20) Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991 ; 266 : 7353-7358.
PubMed
21) Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991 ; 253 : 909-912.
 
22) Matafonov A, Sarilla S, Sun MF, et al. Activation of factor XI by products of prothrombin activation. Blood 2011 ; 118 : 437-445.
PubMed
23) Maas C, Meijers JC, Marquart JA, et al. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci U S A 2010 ; 107 : 9083-9087.
PubMed
24) Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011 ; 118 : 6963-6970.
PubMed
25) Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008 ; 112 : 2810-2816.
PubMed
26) Mutch NJ, Engel R, Uitte de Willige S, et al. Polyphosphate modifies the fibrin network and downregulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010 ; 115 : 3980-3988.
PubMed
27) Dinarvand P, Hassanian SM, Qureshi SH, et al. Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y1 purinergic receptor. Blood 2014 ; 123 : 935-945.
PubMed
28) Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms : involvement of platelet TLR2 and TLR4. Blood 2011 ; 118 : 1952-1961.
PubMed
29) Smith SA, Choi SH, Collins JN, et al. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012 ; 120 : 5103-5110.
PubMed
30) Shenoi RA, Kalathottukaren MT, Travers RJ, et al. Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Sci Transl Med 2014 ; 6 : 260ra150.
PubMed
31) Travers RJ, Shenoi RA, Kalathottukaren MT, et al. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014 ; 124 : 3183-3190.
PubMed
32) Faxalv L, Boknas N, Strom JO, et al. Putting polyphosphates to the test : evidence against plateletinduced activation of factor XII. Blood 2013 ; 122 : 3818-3824.
 
P.75 掲載の参考文献
1) Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res 2008 ; 123 : 8-23.
PubMed
2) Leroyer AS, Isobe H, Leseche G, et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007 ; 49 : 772-777.
PubMed
3) Angelillo-Scherrer A. Leukocyte-derived microparticles in vascular homeostasis. Cir Res 2012 ; 110 : 356-369.
 
4) Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007 ; 97 : 425-434.
PubMed
5) Miyazaki Y, Nomura S, Miyake T, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996 ; 88 : 3456-3464.
PubMed
6) Bernal-Mizrachi L, Jy W, Jimenez JJ, et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003 ; 145 : 962-970.
PubMed
7) Boulanger CM, Scoazec A, Ebrahimian T, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001 ; 104 : 2649-2652.
PubMed
8) Abid-Hussein MN, Boing AN, Sturk A, et al. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb Haemost 2007 ; 98 : 1096-1107.
PubMed
9) Suades R, Padro T, Alonso R, et al. Lipid-lowering therapy with statins reduces microparticle shedding from endotherium, platelets and inflammatory cells. Thromb Haemost 2013 ; 110 : 366-377.
PubMed
10) Perez-Casal M, Downey C, Cutillas-Moreno B, et al. Microparticle- associated endothelial protein C receptor and the induction of cytoprotective and antiinflammatory effects. Haematologica 2009 ; 94 : 387-394.
PubMed
11) Nomura S, Uehata S, Saito S, et al. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 2003 ; 89 : 506-512.
PubMed
12) Nomura S, Shouzu A, Taomoto K, et al. Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan. J Atheroscler Thromb 2009 ; 16 : 878-887.
PubMed
13) Nomura S, Tandon NN, Nakamura T, et al. Highshear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001 ; 158 : 277-287.
 
14) Ghosh A, Li W, Febbraio M, et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributesto thrombosis in mice. J Clin Invest 2010 ; 116 : 4665-4674.
 
15) Wang JG, Geddings JE, Aleman MM, et al. Tumorderived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012 ; 119 : 5543-5552.
 
16) Nomura S, Fujita S, Ozasa R, et al. The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy. Platelets 2011 ; 22 : 396-397.
PubMed
17) Hellum M, Ovstebo R, Brusletto BS, et al. Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock. Thromb Res 2014 ; 133 : 507-514.
PubMed
18) Wen B, Combes V, Bonhoure A, et al. Endotoxininduced monocytic microparticles have contrasting effects on endothelial inflammatory responses. PLoS One 2014 ; 19 : e91597.
 
19) Gheldof D, Chatelain C, Dogne JM, et al. Microparticleassociated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res 2014 ; 134 : 213-214.
PubMed
20) Deregibus MC, Cantaluppi V, Calogero R, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007 ; 110 : 2440-2448.
PubMed
21) Macey MG, Wolf SI, Lawson C. Microparticle formation after exposure of blood to activated endothelium under flow. Cytometry Part A 2010 ; 77A : 761-768.
 
22) Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived microparticles : direct visualization and distinction from platelet-derived microparticles. Blood 2009 ; 113 : 1112-1121.
PubMed
23) Van der Zee PM, Biro E, Trouw LA, et al. C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation. Clincal Immunol 2010 ; 135 : 490-495.
PubMed
24) Koshiar RL, Somajo S, Norstrom E, et al. Erythrocytederived microparticles supporting activated protein C-mediated regulation of blood coagulation. PLoS One 2014 ; 19 : e104200.
 
P.84 掲載の参考文献
1) 血液凝固異常症全国調査運営委員会. 血液凝固異常症全国調査平成26年度報告書 (厚生労働省委託事業). 公益財団法人エイズ予防財団. 2015 ; 1-9.
 
2) 総務省統計局. 人口推計 平成26年10月報 (平成26年5月確定値). http//www.stat.go.jp/data/jinsui/pdf/201410.pdf.
 
3) 藤井輝久, 天野景裕, 渥美達也, 他. インヒビターのない血友病患者に対する止血治療ガイドライン 2013 改訂版. 血栓止血誌 2013 ; 24 : 619-639.
 
4) 田中一郎, 嶋緑倫. 血友病A. 血栓止血誌 2000 ; 11 : 397-405.
 
5) Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001 ; 85 : 958-965.
PubMed
6) The European Association for Haemophilia and Allied Disorders. Factor VIII variant database. http//www.factorviii-db.org.
 
7) The European Association for Haemophilia and Allied Disorders. Factor IX variant database. http//www.factorix.org.
 
8) 高橋幸博, 吉岡章. 小児期の凝固・線溶およびその調節・阻止機構. 日小血会誌 1994 ; 8 : 389-397.
 
9) Mannucci PM. Half-life extension technologies for haemostatic agents. Thromb Haemost 2015 ; 113 : 165-176.
PubMed
10) Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007 ; 357 : 535-544.
PubMed
11) 酒井道生, 瀧正志, 家子正裕, 他. インヒビター保有先天性血友病患者に対する止血治療ガイドライン : 2013年改訂版. 血栓止血誌 2013 ; 24 : 640-658.
 
12) DiMichele D. Inhibitor development in haemophilia B : an orphan disease in need of attention. Br J Haematol 2007 ; 138 : 305-315.
PubMed
13) Peerlinck k, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 2006 ; 12 : 579-590.
PubMed
14) Gouw SC, van der Bom JG, van den Berg HM, et al. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia 2011 ; 17 : 275-281.
 
15) Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009 ; 360 : 1618-1627.
PubMed
16) Gouw SC, van der Bom JG, van der Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A : the CANAL cohort study. Blood 2007 ; 109 : 4648-4654.
 
17) Shirahata A, Fukutake K, Higasa S, et al. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan. Haemophilia 2011 ; 17 : 771-776.
PubMed
18) Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-a and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009 ; 7 : 2006-2015.
PubMed
19) Gouw SC, van der Bom JG, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A : the RODIN study. Blood 2013 ; 121 : 4046-4055.
PubMed
20) Maclean PS, Richards M, Williams M, et al. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011 ; 17 : 282-287.
PubMed
21) Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994 ; 12 : 991-1045.
PubMed
22) Gouw SC, van der Bom JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A : the CANAL cohort study. Blood 2007 ; 109 : 4693-4697.
PubMed
23) Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013 ; 368 : 231-239.
PubMed
24) Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates : a systematic review. J Thromb Haemost 2010 ; 8 : 1256-1265.
PubMed
25) Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006 ; 107 : 46-51.
PubMed
26) 田中一郎, 中宏之, 嶋緑倫. 血友病インヒビター. 血栓止血誌 2000 ; 11 : 559-571.
 
27) Benson G, Auerswald G, Elezovic I, et al. Immune tolerance induction in patients with severe hemophilia with inhibitors : expert panel views and recommendations for clinical practice. Eur J Haematol 2012 ; 88 : 371-379.
 
28) DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction : consensus recommendations. Haemophilia 2007 ; 13 (Suppl.1) : 1-22.
 
29) Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study : a randomized dose comparison. Blood 2012 ; 119 : 1335-1344.
PubMed
30) Oldenburg J, Albert T. Novel products for haemostasis-current status-. Haemophilia 2014 ; 20 : 23-28.
PubMed
P.89 掲載の参考文献
1) Gilbert MS. Prophylaxis : musculoskeletal evaluation. Sem Hematol 1993 ; 30 : 3-6.
 
2) Feldman BM, Funk SM, Bergstrom BM, et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group : validity of the hemophilia joint health score. Arthritis Care Res 2011 ; 63 : 223-230.
 
3) Cotler J, Depalma AF. Hemophilic arthropathy. Clinical Orthopaedics 1956 ; 8 : 163-190.
PubMed
4) Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Related Res 1980 : 153-159.
 
5) Lundin B, Babyn P, Doria AS, et al. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005 ; 11 : 109-115.
PubMed
6) Lundin B, Manco-Johnson ML, Ignas DM, et al. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012 ; 18 : 962-970.
 
7) Hirose J, Takedani H, Koibuchi T. The risk of elective orthopaedic surgery for haemophilia patients : Japanese single-centre experience. Haemophilia 2013 ; 19 : 951-955.
 
8) Hermans C, Hammer F, Lobet S, et al. Subclinical deep venous thrombosis observed in 10% of hemophilic patients undergoing major orthopedic surgery. J Thromb Haemost 2010 ; 8 : 1138-1140.
PubMed
9) Manco-Johnson MJ, Nuss R, Funk S, et al. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000 ; 6 : 649-657.
PubMed
10) Hill FG, Ljung R. Third and fourth Workshops of the European Paediatric Network for Haemophilia Management. Haemophilia 2003 ; 9 : 223-228.
 
11) Funk MB, Schmidt H, Becker S, et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia 2002 ; 8 : 98-103.
PubMed
12) Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2003 ; 9 (Suppl. 1) : 57-63 ; discussion -4.
 
13) Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 2004 ; 10 : 383-389.
PubMed
P.96 掲載の参考文献
1) Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes : vector toolkit for human gene therapy. Mol Ther 2006 ; 14 (3) : 316-327.
PubMed
2) Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008 ; 16 (2) : 280-289.
PubMed
3) Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003 ; 302 (5644) : 415-419.
PubMed
4) Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2004 ; 2 (12) : e423.
PubMed
5) Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000 ; 24 (3) : 257-261.
PubMed
6) Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006 ; 12 (3) : 342-347.
PubMed
7) Sarkar R, Tetreault R, Gao G, et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 2004 ; 103 (4) : 1253-1260.
PubMed
8) Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011 ; 365 (25) : 2357-2365.
PubMed
9) Nathwani AC, Reiss UM, Tuddenham EG, et al. Longterm safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014 ; 371 (21) : 1994-2004.
PubMed
10) McIntosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 2013 ; 121 (17) : 3335-3344.
PubMed
11) Mimuro J, Mizukami H, Shima M, et al. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. J Med Virol 2014 ; 86 (11) : 1990-1997.
PubMed
12) Mimuro J, Mizukami H, Hishikawa S, et al. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther 2013 ; 21 (2) : 318-323.
PubMed
13) Matsui H, Fujimoto N, Sasakawa N, et al. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A. PLoS One 2014 ; 9 (8) : e104957.
PubMed
14) Roth DA, Tawa NE, Jr., O'Brien JM, et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001 ; 344 (23) : 1735-1742.
PubMed
15) Follenzi A, Benten D, Novikoff P, et al. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 2008 ; 118 (3) : 935-945.
PubMed
16) Kumaran V, Benten D, Follenzi A, et al. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. J Thromb Haemost 2005 ; 3 (9) : 2022-2031.
PubMed
17) Shi Q, Fahs SA, Kuether EL, et al. Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. Blood 2010 ; 116 (16) : 3049-3057.
 
18) Matsui H, Shibata M, Brown B, et al. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells 2007 ; 25 (10) : 2660-2669.
PubMed
19) Ozelo MC, Vidal B, Brown C, et al. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. Blood 2014 ; 123 (26) : 4045-4053.
 
20) Moayeri M, Ramezani A, Morgan RA, et al. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther 2004 ; 10 (5) : 892-902.
PubMed
21) Ohmori T, Ishiwata A, Kashiwakura Y, et al. Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets. Mol Ther 2008 ; 16 (8) : 1359-1365.
PubMed
22) Ohmori T, Mimuro J, Takano K, et al. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter : in vivo model for platelet-targeting gene therapy. FASEB J 2006 ; 20 (9) : 1522-1524.
PubMed
23) Shi Q, Wilcox DA, Fahs SA, et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 2007 ; 5 (2) : 352-361.
PubMed
24) Du LM, Nurden P, Nurden AT, et al. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun 2013 ; 4 : 2773.
PubMed
25) Tatsumi K, Sugimoto M, Lillicrap D, et al. A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A. PLoS One 2013 ; 8 (12) : e83280.
 
26) Watanabe N, Ohashi K, Tatsumi K, et al. Genetically modified adipose tissue-derived stem/stromal cells, using simian immunodeficiency virus-based lentiviral vectors, in the treatment of hemophilia B. Hum Gene Ther 2013 ; 24 (3) : 283-294.
PubMed
27) Kashiwakura Y, Ohmori T, Mimuro J, et al. Intraarticular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor VIII-deficient mice. J Thromb Haemost 2012 ; 10 (9) : 1802-1813.
PubMed
28) Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011 ; 475 (7355) : 217-221.
 
29) Park CY, Kim J, Kweon J, et al. Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proc Natl Acad Sci U S A 2014 ; 111 (25) : 9253-9258.
 
30) Matsui H, Shibata M, Brown B, et al. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells. Blood 2009 ; 114 (3) : 677-685.
 
31) Madoiwa S, Yamauchi T, Hakamata Y, et al. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. J Thromb Haemost 2004 ; 2 (5) : 754-762.
PubMed
32) Markusic DM, Hoffman BE, Perrin GQ, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med 2013 ; 5 (11) : 1698-1709.
PubMed
P.106 掲載の参考文献
1) Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haemtol 1996 ; 9 : 331-54.
PubMed
2) 田中一郎, 天野景裕, 瀧正志, 他. わが国における後天性凝固因子インヒビターの実態に関する3年間の継続調査 : 予後因子に関する検討. 日本血栓止血学会誌 2008 ; 19 : 140-153.
 
3) Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A : results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012 ; 10, 622-631.
PubMed
4) Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom : a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007 ; 109 : 1870-1877.
PubMed
5) Tufano A, Coppoia A, Guida A, et al. Acquired haemophilia a in the elderly : case reports. Curr Gerontol Geriatr Res 2010 ; 2010 : 927503.
PubMed
6) El-Osta H, Reddy P, Deutsch JM, et al. Acquired factor VIII inhibitors : case reports of paclitaxel and penicillin-induced entities. Blood Coagul Fibrinolysis 2009 ; 20 : 719-721.
PubMed
7) O'Reilly RA, Hamilton RD. Acquired hemophilia, meningioma, and diphenylhydantoin therapy. J Neurosurg 1980 ; 53 : 600-605.
PubMed
8) Franchini M, Mannucci PL. Acquired haemophilia A : a 2013 update. Thromb Haemost 2013 ; 110 : 1114-1120.
 
9) Tengborn L, Baudo F, Huth-Kuhne A, et al. Pregnancy-associated acquired haemophilia A : results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012 ; 119 : 1529-1537.
PubMed
10) Hauser I, Schneider B, Lechner K, et al. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 1995 ; 73 : 1-5.
 
11) Franchini M, Postpartum acquired factor VIII inhibitors. Am J Hematol. 2006 ; 81 : 768-773.
PubMed
12) Bonfanti C, Crestani S, Frattini F, et al. Role of rituximab in the treatment of postpartum acquired haemophilia A : a systematic review of the literature. Blood Transfus. 2014 ; 17 : 1-5.
 
13) Baudo F, de Cataldo F. Acquired factor VIII inhibitors in pregnancy : data from the Italian Haemophilia Register relevant to clinical practice. BJOG 2003 ; 110 : 311-4.
PubMed
14) 後天性血友病A診療ガイドライン作成委員会. 後天性血友病A診療ガイドライン. 日本血栓止血学会. 東京. 2011.
 
15) 田中一郎. 抗第VIII因子抗体. In : 日本検査血液学会 (編). スタンダード検査血液学. 第2版. 東京 : 医歯薬出版, 2013 : 169-170.
 
16) Verbruggen, B, Novakova I, Wessels H, et al. The Nijmegen modification of the Besethda assay for factor VIII : C inhibitor : Improved specificity and reliability. Thromb Haemost 1995 ; 73 : 247-251.
PubMed
17) 田中一郎, 中宏之, 嶋緑倫. 血友病インヒビター. 日本血栓止血学会誌 2000 ; 11 : 559-571.
 
18) Mazodier K, Arnaud L, Mathian A. et al. Lupus anticoagulant-hypoprothrombinemia syndrome : report of 8 cases and review of the literature. Medicine (Baltimore) 2012 ; 91 : 251-60.
PubMed
19) 家子正裕. クロスミキシング試験を臨床に活かすには. 医療と検査機器・試薬 2012 : 35 : 867-872.
Medical*Online
20) Collins P, Baudo F, Huth-Kuhne A, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes 2010 ; 3 : 161.
 
21) Baudo F, Caimi T, de Cataldo F. Diagnosis and treatment of acquired haemophilia. Haemophilia 2010 ; 16 : 102-106.
PubMed
22) Huth-Kuhne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009 ; 94 : 566-575.
PubMed
23) 嶋緑倫, 田中一郎, 川合陽子, 他. 本邦における血液凝固後天性インヒビターの実態. 日本血栓止血学会誌 2003 : 14 : 107-121.
 
24) Hay CR, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors : a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006 ; 133 : 591-602.
PubMed
25) Franchini M, Gandini G, Di Paolantonio T, et al. Acquired hemophilia A : a concise review. Am J Hematol 2005 ; 80 : 55-63.
PubMed
26) 野上恵嗣. 後天性凝固因子インヒビターの基礎と病態. 臨床血液 2013 ; 54 : 1907-14.
 
27) Batlle J, Gomez E, Rendal E, et al. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol 1996 ; 72 : 321-326.
PubMed
28) Hu GL, Okita DK, Diethelm-Okita BM, et al. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003 ; 1 : 2159-2166.
PubMed
29) Lacroix-Desmazes S, Navarrete AM, Andre S, et al. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008 ; 112 : 240-249.
PubMed
30) Oldenburg J, Zeitler H, Pavlova A. Genetic markers in acquired haemophilia. Haemophilia 2010 : 16 (Suppl. 3) : 41-45.
 
31) 田中一郎, 嶋緑倫. 後天性血友病 : 本邦における実態と抗第VIII因子自己抗体の免疫生化学的特性. 臨床血液 2005 ; 46 : 91-8.
 
32) Prescott R, Nakai H, Saenko EL, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997 ; 89 : 3663-36p71.
PubMed
33) Matsumoto T, Nogami K, Ogiwara K, et al. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost 2012 ; 107 : 288-301.
PubMed
P.113 掲載の参考文献
1) Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease : a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004 ; 10 : 199-217.
PubMed
2) Pasi KJ, Collins PW, Keeling DM, et al. : Management of von Willebrand disease : a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004 ; 10 : 218-231..
PubMed
3) Nicols WL, Hultin MB, James AH, et al. von Willebrand disease (vWD) : evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008 ; 14 : 171-232..
 
4) Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome. Blood 2011 ; 117 : 6777-6785.
 
5) 毛利博 : 後天性von Wilebrand症候群. In : 関西血栓フォーラム (編). 関西血栓フォーラム 2002 血小板血栓形成の分子機構. 奈良 : アイプリコム出版, 2002 : 106-116.
 
6) Federici AB, Rand JH, Bucciarelli P, et al. acquired von Willebrand syndrome : Data from an international registry. Thromb Haemost 2000 ; 84 : 345-349.
 
7) Tiede A, Priesack J, Werwitzke S, et al. Diagnostic workup of patients with acquired von Willebrand syndrome : a retrospective single-centre cohort study. J Thromb Haemost 2008 ; 6 : 569-576.
 
8) Federici AB : Acquired von Willebrand syndrome : Is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost 2008 ; 6 : 569-576.
 
9) Vincentelli A, Sussen S, Le Toumeau T, et al. : Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003 ; 349 : 343-349.
 
10) Mohri H, Motomura S, Kanamori H, et al. : Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998 ; 91 : 3623-3629.
 
11) FedericiAB : Acquired von Willebrand syndrome associated with hypothyroidism : a mild bleeding disorder to be further investigated. Semin Thromb Hemost 2011 ; 37 : 35-40.
 
12) Coppola A, Tufano A, Di Capua M et al. Bleeding and thrombosis in multiple myeloma and realted plasma cell disorders. Semin Thromb Hemost 2011 ; 37 : 929-945.
 
13) Tefferi A : Polycythemia vera and essential thrombocytemia : 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012 ; 87 : 285-293.
PubMed
14) Franchini M, Mannucci PM. : Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thromb Haemost 2014 ; 112 : 427-431.
PubMed
15) Siaka C, Rugeri L, Caron C, et al. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 9 : 303-308, 2003.
 
16) Federici AB, Stabile F, Castaman G, et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance : Comparison of three different therapeutic approaches. Blood 1998 ; 92 : 2707-2711.
 
P.124 掲載の参考文献
1) Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012 ; 95 : 362-370.
PubMed
2) 一瀬白帝. 後天性血友病 XIII (13) の実態調査, 発症機序の解明と治療方法の開発に関する研究. 厚生労働科学研究費補助金 難治性疾患克服研究事業 平成22年度総括・分担研究報告書. 2011.
 
3) Egbring R, Kroniger A, Seitz R. Factor XIII deficiency : pathogenic mechanisms and clinical significance. Semin Thromb Hemost 1996 ; 22 : 419-425.
PubMed
4) Ichinose A. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 2011 ; 37 : 382-388.
PubMed
5) Lawrie AS, Green L, Mackie IJ, et al. Factor XIII--an under diagnosed deficiency--are we using the right assays? J Thromb Haemost 2010 ; 8 : 2478-2482.
PubMed
6) Hanafusa N, Satonaka H, Doi K, et al. Virus removal and eradication by modified double filtration plasmapheresis decreases factor XIII levels. Ther Apher Dial 2010 ; 14 : 287-291.
PubMed
7) Ogawa Y, Mihara M, Souri M, et al. Complete remission achieved by steroid pulse therapy following rituximab treatment in a case with autoimmune haemorrhaphilia due to anti-factor XIII antibodies. Thromb Haemost 2014 ; 112, 831-833.
 
8) 一瀬白帝. 診断困難な (原因不明の) 出血性後天性凝固異常症の総合的診療指針の作成に関する研究. 厚生労働科学研究費補助金 難治性疾患等克服研究事業 (難治性疾患克服研究事業) 平成24～25年度総合研究報告書. 2014.
 
9) Hayakawa K, Tamura S, Gima H, et al. Successful treatment of chronic disseminated intravascular coagulation using recombinant human soluble thrombo-modulin in a dialysis patient with dissecting aortic aneurysm. Rinsho Ketsueki 2014 Nov ; 55 (11) : 2300-5.
 
10) Kawano H, Yamamoto D, Uchihashi Y, et al. Severe inhibitor-negative acquired factor XIII/13 deficiency with aggressive subdural haemorrhage. Blood Coagul Fibrinolysis 2013 ; 24 : 638-641.
PubMed
11) Ichinose A. Japanese Collaborative Research Group (JCRG) on AH13 Hemorrhagic Acquired Coagulopathies. Inhibitors of Factor XIII/13 in older patients. Semin Thromb Hemost 2014 ; 40 : 704-711.
 
12) Ichinose A, Souri M. Japanese collaborative research group on "Acquired haemorrha-philia due to factor XIII deficiency". As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011 ; 105 : 925-927.
 
13) Ichinose A, Osaki T, Souri M, et al. Clinical features of 32 new Japanese cases with autoimmune haemorrhaphilia due to anti-factor XIII antibodies. Haemophilia 2015 ; in press (doi : 10.1111/hae.12677).
 
14) Nakamura S, Kato A, Sakata Y, et al. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988 ; 68 : 313-319.
PubMed
15) Teruya J, Kinoshita T, Yoshimura Y, et al. An inhibitor to factor VIII interacting with its activated catalytic subunit. Rinsho Ketsueki 1986 ; 27 : 1680-1687.
PubMed
16) Lorand L. Acquired inhibitors of fibrin stabilization : A class of hemorrhagic disorders of diverse origins. In : Green D, editors. Anticoagulants, Physiologic, Pathologic and Pharmacologic. Boca Raton, FL : CRC Press, 1994 : 169-191.
 
17) Egbring R, Kroniger A, Seitz R. Erworbene Inhibitoren gegen Faktor XIII. Hamostaseologie 1996 ; 16 : 174-179.
 
18) Tone K, Lalu M, Kilty SJ, et al. Airway Compromise and Perioperative Management of a Patient with Acquired Factor XIII Inhibitor. A A Case Rep 2015 ; 4 : 120-124.
PubMed
19) 一瀬白帝. 後天性凝固異常症のP. O. C. テストによる迅速診断システムの開発に関する研究. 厚生労働科学研究委託費 難治性疾患実用化研究事業 平成26年度委託業務成果報告書. 2015.
 
20) Kotake T, Souri M, Takada K, et al. Report of a patient with chronic intractable autoimmune hemorrhaphilia due to anti-Factor XIII/13 antibodies who died of hemorrhage after sustained clinical remission for three years. Int J Hematol 2015 ; in press (doi : 10.1007/s12185-015-1754-8).
 
21) Sugiyama H, Uesugi H, Suzuki S, et al. Aggressive fatal case of autoimmune hemorrhaphilia resulting from anti-Factor XIII antibodies. Blood Coagul Fibrinolysis 2013 ; 24 : 85-89.
PubMed
22) Ishida F, Okubo K, Ito T, et al. Spontaneous regression of the inhibitor against the coagulation factor XIII A subunit in acquired factor XIII deficiency. Thromb Haemost 2010 ; 104 : 1284-1285.
PubMed
23) Lewis JH, Szeto IL, Ellis LD, et al. An acquired inhibitor to coagulation factor 13. Johns Hopkins Med J 1967 ; 120 : 401-407.
PubMed
24) Lorand L, Jacobsen A, Bruner-Lorand J. A pathological inhibitor of fibrin cross-linking. J Clin Invest 1968 ; 47 : 268-273.
 
25) Otis PT, Feinstein DI, Rapaport SI, et al. An acquired inhibitor of fibrin stabilization associated with isoniazid therapy : clinical and biochemical observations. Blood 1974 ; 44 : 771-781.
PubMed
26) Fear JD, Miloszewski KJ, Losowsky MS. An acquired inhibitor of factor XIII with a qualitative abnormality of fibrin cross-linking. Acta Haematol 1984 ; 71 : 304-309.
PubMed
27) 一瀬白帝. 診断困難な (原因不明の) 出血性後天性凝固異常症の総合的診療指針の作成に関する研究. 厚生労働科学研究費補助金 難治性疾患等克服研究事業 (難治性疾患克服研究事業) 平成25 年度総括・分担研究報告書 2014.
 
28) Ichinose A, Souri M. Reduced difference of α2-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies. Int J Hematol 2012 ; 95 : 47-50.
 
29) Souri M, Osaki T, Ichinose A. Anti-factor XIII A subunit (FXIII-A) autoantibodies block FXIII-A2B2 assembly and steal FXIII-A from native FXIII-A2B2. J Thromb Haemost 2015 ; 13 : 802-814.
 
30) Souri M, Osaki T, Ichinose A. The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking. J Biol Chem 2015 ; 290 : 12027-12039.
PubMed
31) Osaki T, Sugiyama D, Magari Y, et al. Rapid immunochromatographic test for detection of anti-factor XIII A subunit antibodies can diagnose 90 % of cases with autoimmune haemorrhaphilia XIII/13. Thromb Haemost 2015 ; 113 : 1347-1356.
PubMed
32) 厚生労働省健康局疾病対策課. 難病の患者に対する医療等に関する法律第五条第一項の規定に基づき厚生労働大臣が指定する指定難病及び同法第七条第一項第一号の規定に基づき厚生労働大臣が定める病状の程度の一部を改正する件 (平成26年5月13日厚生労働省告示第266号). http://wwwhourei.mhlw.go.jp/hourei/doc/hourei/H150514H0010.pdf
 
P.132 掲載の参考文献
1) Taylor Jr FB, Wada H, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation : On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 2001 ; 86 : 1327-1330.
 
2) 中川雅夫. 本邦における播種性血管内凝固 (DIC) の発症頻度・原因疾患に関する調査報告. 厚生省特定疾患血液系疾患調査研究班血液凝固異常症分科会, 平成10年度研究業績報告書. 1999 : 57-64.
 
3) Wada H. Disseminated intravascular coagulation. Clin Chim Acta 2004 ; 344 : 13-21.
PubMed
4) Wada H, Matsumoto T, Hatada T. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol. 2012 ; 5 : 643-652.
PubMed
5) Wada H, Matsumoto T, Yamashita Y, et al. Disseminated Intravascular Coagulation : Testing and Diagnosis. Clin Chim Acta. 2014 ; 436 : 130-134.
PubMed
6) Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010 ; 107 : 15880-15885.
PubMed
7) Wada H, Asakura H, Okamoto K, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee : Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010 ; 125 : 6-11.
PubMed
8) 日本血栓止血学会学術標準化委員会DIC部会. 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス, 日本血栓止血学会誌, 2009 ; 20 : 77-113.
 
9) Kobayashi N, Maegawa T, Takada M, et.al. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haemotol 1983 ; 49 : 265-275.
 
10) Gando S, Iba T, Eguchi Y, et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group : A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med 2006 ; 34 : 625-31.
 
11) Takemitsu T, Wada H, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost. 2011 ; 105 (1). 40-44.
PubMed
12) DIC診断基準作成委員会. 日本血栓止血学会DIC診断基準暫定案. 日本血栓止血学会誌 2014 ; 25 : 629-646.
 
13) Wada H, Wakita Y, Nakase T, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 1995 ; 74 : 848-852.
 
14) Okamoto K, Wada H, Hatada T, et al ; Japanese Society of Thrombosis Hemostasis/DIC subcommittee : Frequency and hemostatic abnormalities in pre-DIC patients. Thromb Res 2010 ; 126 : 74-78.
PubMed
15) Gando S, Iba T, Eguchi Y, et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group : A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med 2006 ; 34 : 625-631.
 
16) Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis : a 5-year overview. J Thromb Haemost 2007 ; 5 : 604-606.
PubMed
17) Wada H, Hatada T, Okamoto K, et al. Modified nonovert DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol, 2010 ; 85 : 691-69.
PubMed
18) Wada H, Thachil J, Di Nisio M, et al ; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013 ; 11 : 761-767.
 
19) Wada H, Asakura H, Okamoto K, et al ; Japanese Society of Thrombosis Hemostasis/DIC subcommittee : Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010 ; 125 : 6-11.
PubMed
20) Wada H, Okamoto K, Iba T, et al : Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan". Thromb Res, 2014 ; 134 : 924-925.
 
21) Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006 ; 4 : 90-97.
 
22) Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007 ; 5 : 31-41.
PubMed
23) Mimuro J, Takahashi H, Kitajima I, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res, 2013 ; 131 : 436-443.
PubMed
P.139 掲載の参考文献
1) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement of an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 ; 4 : 295-306.
 
2) Sugiura-Ogasawara M, Suzuki S, Ozaki Y, et al. frequency of recurrent miscarriage and its influence on further marital relationship and illness : The Okazaki Cohort Study in Japan. submitted. J Obstet Gynaecol Res 2013 ; 39 : 126-131.
 
3) Sugiura-Ogasawara M, Ozaki Y, Kitaori T, et al. Midline uterine defect size correlated with miscarriage of euploid embryos in recurrent cases. Fertil Steril 2010 ; 93 : 1983-1988.
PubMed
4) Sugiura-Ogasawara M, Ozaki Y, Katano K, et al. Abnormal embryonic karyotype is the most frequent cause of recurrent miscarriage. Hum Reprod 2012 ; 27 : 2297-2303.
PubMed
5) Pengo V, Tripodi A, Reber G, et al ; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009 ; 7 : 1737-1740.
PubMed
6) Katano K, Aoki K, Sasa H, et al. beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996 ; 11 : 509-512.
 
7) Yamada H, Atsumi T, Kobashi G, et al. Antiphospholipid antibodies increase the risk of pregnancy induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009 ; 79 : 188-195.
PubMed
8) Ogasawara MS, Aoki K, Katano K, et al. Factor XII but not protein C, protein S, antithrombin III or factor XIII as a predictor of recurrent miscarriage. Fertil Steril 2001 ; 75 : 916-919.
 
9) Sugi T, Matsubayashi H, Inomo A, et al. Antiphosphati dylethanolamine antibodies in recurrent early pregnancy loss and mid-to late pregnancy loss. J Obstet Gynecol Res 2004 ; 30 : 326-332.
 
10) Obayashi S, Ozaki Y, Sugi T, et al. Antiphos pha tidylethanolamine antibodies might not be independent risk factors for further miscarriage in patients suffering recurrent pregnancy loss. J Reprod Immunol 2010 ; 85 : 41-45.
 
11) Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, nonautoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study4-NOHA4. Thromb Haemost 2000 ; 84 : 228-236.
 
12) Kitaori T, Sugiura-Ogasawara M, Oku K, et al. Determination of clinically significant tests for antiphospholipid antibodies and cutoff levels for obstetric antiphospholipid syndrome. Lupus in press.
 
13) Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012 ; 64 : 2311-2318.
PubMed
14) Ogasawara M, Aoki K, Kajiura S, et al. Are antinuclear antibodies predictive of recurrent miscarriage? Lancet 1996 ; 347 : 1183-1184.
PubMed
15) Lubbe WF, Butler WS, Palmer SJ, et al. Lupus-anticoagulant in pregnancy. Lancet 1983 ; 1 : 1361-1366.
PubMed
16) Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies : a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992 ; 166 : 1318-1323.
PubMed
17) Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phopholipid antibodies (or antiphospholipid antibodies). BMJ 1997 ; 314 : 253-257.
PubMed
18) Kutteh WH. Antiphospholipid antibodies-associated recurrent pregnancy loss : treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996 ; 174 : 1584-1589.
PubMed
19) Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss : a systematic review and meta-analysis. Obstet Gynecol 2010 ; 115 : 1256-1262.
 
20) Rand JH, Wu XX, Guller S, et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphopholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994 ; 171 : 1566-1572.
 
21) Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004 ; 10 : 1222-1226.
PubMed
22) Quenby S, Mountfield S, Chamley L, et al. Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril 2005 ; 83 : 691-698.
PubMed
23) Kaandrop SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010 ; 362 : 1586-1596.
PubMed
24) Asano E, Ebara T, Yamada-Namikawa C, et al. Genotyping analysis for the 46 C/T polymorphism of coagulation factor XII and the involvement of factor XII activity in patients with recurrent pregnancy loss. PlosOne 2014 ; 9 (12) : e114452.
 

2部 ショック・敗血症と凝固・炎症系

P.147 掲載の参考文献
1) 北村肇, 補体学入門. 学際企画株式会社, 2010.
 
2) 大井洋之, 木下タロウ, 松下操, 補体への招待. メジカルビュー社, 2011.
 
3) Vallota EH, Muller-Eberhard HJ. Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med 1973 ; 137 (5) : 1109-1123.
PubMed
4) Brier A.M, et al. Inflammation and herpes simplex virus : release of a chemotaxis-generating factor from infected cells. Science 1970 ; 170 (3962) : 1104-1106.
PubMed
5) Oikonomopoulou K, et al. Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol 2012 ; 34 (1) : 151-165.
PubMed
6) Huber-Lang M, et al. Generation of C5a in the absence of C3 : a new complement activation pathway. Nat Med 2006 ; 12 (6) : 682-687.
PubMed
7) Amara U, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010 ; 185 (9) : 5628-5636.
PubMed
8) Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981 ; 153 (3) : 665-676.
PubMed
9) Gulla KC, et al. Activation of mannan-binding lectinassociated serine proteases leads to generation of a fibrin clot. Immunology 2009 ; 129 (4) : 482-495.
PubMed
10) Del Conde I, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005 ; 201 (6) : 871-879.
PubMed
11) Skoglund C, et al. C1q induces a rapid up-regulation of P-selectin and modulates collagen- and collagen-related peptide-triggered activation in human platelets. Immunobiology 2010 ; 215 (12) : 987-995.
PubMed
12) Peerschke, EI, Reid KB, Ghebrehiwet B. Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med 1993 ; 178 (2) : 579-587.
PubMed
13) Gushiken FC, et al. Abnormal platelet function in C3-deficient mice. J Thromb Haemost 2009 ; 7 (5) : 865-870.
PubMed
14) Qin X, et al. Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity 2003 ; 18 (2) : 217-227.
PubMed
15) Hamad OA, et al. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 2010 ; 184 (5) : 2686-2692.
PubMed
16) Lidington EA, Haskard DO, Mason JC. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 2000 ; 96 (8) : 2784-2792.
PubMed
17) Campbell WD, et al. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002 ; 46 (2) : 131-134.
PubMed
18) Barthel D, Schindler S, Zipfel PF. Plasminogen is a complement inhibitor. J Biol Chem 2012 ; 287 (22) : 18831-18842.
PubMed
19) Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood 2014 ; 124 (18) : 2804-2811.
PubMed
20) 厚生労働省「特発性造血障害に関する調査研究班」. 発作性夜間ヘモグロビン尿症の診療の参照ガイド (平成22年度改訂版). 2011. http://square.umin.ac.jp/compl/common/images/disease-information/pnh/PNH-1.pdf
 
21) Miyata T, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993 ; 259 (5099) : 1318-1320.
 
22) Takeda J, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993 ; 73 (4) : 703-711.
PubMed
23) Rother RP, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007 ; 25 (11) : 1256-1264.
PubMed
24) Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 2014 ; 165 (2) : 306-320.
PubMed
25) Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013 ; 121 (25) : 4985-4996 ; quiz 5105.
PubMed
26) Hoekstra J, et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome : findings from a cohort study. J Hepatol 2009 ; 51 (4) : 696-706.
PubMed
27) Weitz JI. Heparan sulfate : antithrombotic or not? J Clin Invest 2003 ; 111 (7) : 952-954.
 
28) HajMohammadi S, et al. Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis. J Clin Invest 2003 ; 111 (7) : 989-999.
PubMed
29) 非典型溶血性尿毒症症候群診断基準作成委員会. 日本腎臓学会作成の診療ガイドライン 非典型溶血性尿毒症症候群 (aHUS) 診断基準. 2013. http://www.jsn.or.jp/guideline/pdf/ahus2013.pdf
 
30) 一般社団法人日本補体学会HAEガイドライン作成委員会. 遺伝性血管性浮腫 (HAE) のガイドライン改訂2014年版. 2014. http://square.umin.ac.jp/compl/disease-information/.
 
P.154 掲載の参考文献
1) Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature Rev Immunol 2013 ; 13 (1) : 34-45.
 
2) Luo D, Szaba FM, Kummer LW, et al. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gramnegative bacterium Yersinia enterocolitica. J Immunol 2011 ; 187 (4) : 1866-1876.
 
3) Sun H, Wang X, Degen JL, et al. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009 ; 113 (6) : 1358-1364.
PubMed
4) Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nature Med 2010 ; 16 (8) : 887-896.
PubMed
5) Reinhardt C, von Bruhl ML, Manukyan D, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008 ; 118 (3) : 1110-1122.
PubMed
6) Pawlinski R, Pedersen B, Schabbauer G, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 2004 ; 103 (4) : 1342-1347.
 
7) Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 1975 ; 30 (3) : 311-316.
PubMed
8) Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003 ; 197 (11) : 1585-1598.
PubMed
9) Pawlinski R, Wang JG, Owens AP 3rd, et al. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood 2010 ; 116 (5) : 806-814.
PubMed
10) von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. Journal Exp Med 2012 ; 209 (4) : 819-835.
PubMed
11) Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Med 2007 ; 13 (4) : 463-469.
PubMed
12) Sreeramkumar V, Adrover JM, Ballesteros I, et al. Neutrophils scan for activated platelets to initiate inflammation. Science 2014 ; 346 (6214) : 1234-1238.
PubMed
13) Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004 ; 303 (5663) : 1532-1535.
PubMed
14) Branzk N, Lubojemska A, Hardison SE, et al. Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nature Immunol 2014 ; 15 (11) : 1017-1025.
 
15) Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010 ; 107 (36) : 15880-15885.
PubMed
16) McDonald B, Urrutia R, Yipp BG, et al. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 2012 ; 12 (3) : 324-333.
PubMed
17) Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care 2014 ; 2 (1) : 67.
PubMed
18) Kono H, Rock KL. How dying cells alert the immune system to danger. Nature Rev 2008 ; 8 (4) : 279-289.
PubMed
19) Ito T, Kawahara K, Nakamura T, et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 2007 ; 5 (1) : 109-116.
PubMed
20) Furlan-Freguia C, Marchese P, Gruber A, et al. P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J Clin Invest 2011 ; 121 (7) : 2932-2944.
PubMed
21) Loof TG, Morgelin M, Johansson L, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011 ; 118 (9) : 2589-2598.
PubMed
22) Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin (ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 2004 ; 113 (11) : 1596-1606.
PubMed
23) Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001 ; 86 (5) : 1327-1330.
 
24) Levi M, Ten Cate H. Disseminated intravascular coagulation. N Eng J Med 1999 ; 341 (8) : 586-592.
 
25) Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005 ; 128 (4) : 2864-2875.
PubMed
26) Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991 ; 33 (3) : 127-134.
PubMed
27) Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005 ; 94 (5) : 975-979.
PubMed
28) Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999 ; 285 (5425) : 248-251.
PubMed
29) Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005 ; 115 (5) : 1267-1274.
 
30) Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004 ; 101 (1) : 296-301.
PubMed
31) Shirakawa K, Naitou K, Hirose J, et al. The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models. Crit Care 2010 ; 14 (Suppl 2) : S7.
 
32) Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infection Chemotherapy 2011 ; 17 (6) : 764-769.
 
33) Masson S, Caironi P, Fanizza C, et al. Circulating presepsin (soluble CD14 subtyp e) as a marker of host response in patients with severe sepsis or septic shock : data from the multicenter, randomized ALBIOS trial. Intensive Care Med 2015 ; 41 (1) : 12-20.
PubMed
34) Takahashi G, Shibata S, Ishikura H, et al. Presepsin in the prognosis of infectious diseases and diagnosis of infectious disseminated intravascular coagulation : A prospective, multicentre, observational study. Eur J Anaesthesiol 2015 ; 32 (3) : 199-206.
PubMed
35) Kotera A, Sagishima K, T ashiro T, et al. A validation of presepsin levels in kidney dysfunction patients : four case reports. J Intensive Care 2014 ; 2 (1) : 63.
 
P.161 掲載の参考文献
1) Stein LD. Human genome : end of the beginning. Nature 2004 ; 431 (7011) : 915-916.
PubMed
2) Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012 ; 489 (7414) : 57-74.
 
3) Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993 ; 75 (5) : 843-854.
 
4) Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993 ; 75 (5) : 855-862.
 
5) Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010 ; 11 (9) : 597-610.
PubMed
6) Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010 ; 466 (7308) : 835-840.
PubMed
7) Witkos TM, Koscianska E, Krzyzosiak WJ. Practical Aspects of microRNA Target Prediction. Curr Mol Med 2011 ; 11 (2) : 93-109.
PubMed
8) Ambros V. MicroRNA pathways in flies and worms : growth, death, fat, stress, and timing. Cell 2003 ; 113 (6) : 673-676.
PubMed
9) Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009 ; 19 (1) : 92-105.
 
10) Croce CM. Oncogenes and cancer. N Engl J Med 2008 ; 358 (5) : 502-511.
PubMed
11) Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet 2003 ; 35 (3) : 215-217.
PubMed
12) Suarez Y, Fernandez-Hernando C, Yu J, et al. Dicerdependent endothelial microRNAs are necessary for postnatal ang iogenesis. Proc Natl Acad Sci U.S.A 2008 ; 105 (37) : 14082-14087.
 
13) Schmidt M, Paes K, De Maziere A, et al. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development 2007 ; 134 (16) : 2913-2923.
PubMed
14) Fish JE, Santoro MM , Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008 ; 15 (2) : 272-284.
PubMed
15) Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific mi croRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008 ; 15 (2) : 261-271.
 
16) Harris TA, Yamakuchi M, Ferlito M, et al. Micro RNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U.S.A. 2008 ; 105 (5) : 1516-1521.
PubMed
17) Versteeg HH , Heemskerk JW, Levi M, et al. New fundamentals in hemostasis. Physiol Rev 2013 ; 93 (1) : 327-358.
PubMed
18) Zhai PF, Wang F, Su R, et al. The regulatory roles of microRNA-146b-5p and its target platelet-derived growth factor receptor alpha (PDGFRA) in er ythro-poiesis and megakaryocytopoiesis. J Biol Chem 2014 ; 289 (33) : 22600-22613.
 
19) Garzon R, Pichiorri F, Palumbo T, et al. Micro RNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U .S.A. 2006 ; 103 (13) : 5078-5083.
PubMed
20) Landry P, Plante I, Ouellet DL, et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009 ; 16 (9) : 961-966.
PubMed
21) Leierseder S, Petzold T, Zhang L, et al. MiR-223 is dispensable for platelet production and function in mice. Thromb Haemost 2013 ; 110 (6) : 1207-1214.
PubMed
22) Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets : suggested role for platelet microRNA. J Thromb Haemos t 2010 ; 8 (2) : 369-378.
 
23) Edelstein LC, Simon LM, Montoya RT, et al. Racial differences in human platelet PAR4 reactivity reflect expre ssion of PCTP and miR-376c. Nat Med 2013 ; 19 (12) : 1609-1616.
 
24) Monroe DM, Key NS. The tissue factor-factor VIIa complex : procoagulant activity, regulation, an d multitasking. J Thromb Haemost 2007 ; 5 (6) : 1097-1105.
 
25) Garnier D, Magnus N, D'Asti E, et al. Genetic pathways linking hemostasis and cancer. Thromb Res 2012 ; 129 (Suppl 1) : S22-S29.
 
26) Regina S, Valentin JB, Lachot S, et al. Increased tissue factor expression is associated with reduced s urvival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem 2009 ; 55 (10) : 1834-1842.
 
27) Li S, Chen H, Ren J, et al. MicroRNA-223 inhibits tissue factor expression in vascular endothelial cells. Atherosc lerosis 2014 ; 237 (2) : 514-520.
 
28) Yu YH, Wu DS, Huang FF, et al. MicroRNA-20b and ERK1/2 pathway independently regulate the expression of tissue factor in hematopoietic and trophoblastic differentiation of human embryonic stem cells. Stem Cell Res Ther 2013 ; 4 (5) : 121.
PubMed
29) Ma S, Chan YP, Kwan P S, et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. C ancer Res 2011 ; 71 (2) : 583-592.
 
30) Laffont B, Corduan A, Ple H, et al. Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. Blood 2013 ; 122 (2) : 253-261.
PubMed
31) Sun X, Belkin N, Feinberg MW. Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep. 2013 ; 15 (12) : 372.
PubMed
32) Edelstein LC, McKenzie SE, Shaw C, et al. MicroRNAs in platelet production and activation. J Thromb Haemost. 2013 ; 11 (Suppl 1) : 340-50.
 
33) Eisenreich A, Leppert U. The impact of microRNAs on the regulation of tissue factor biology. Trends Cardiovasc Med 2014 ; 24 (3) : 128-132.
PubMed
P.168 掲載の参考文献
1) Brohi K, Singh J, Heron M et al. Acute traumatic coagulopathy. J Trauma 2003 ; 54 : 1127-1130.
PubMed
2) 丸藤哲, 亀上隆, 澤村淳, ほか : 外傷後に見られる血液凝固線溶系の変化-新しい考え方と治療法. 日救急医会誌 2006 ; 17 : 629-644.
 
3) Gando S : Acute coagulopathy of trauma shock and coagulopathy of trauma : A rebuttal. You are going down the wrong path. J Trauma. 2009 ; 67 : 381-383.
 
4) 丸藤哲, 澤村淳, 早川峰司, ほか : 外傷急性期の血液凝固線溶系-現在の世界的論点を整理する-. 日救急医会誌 2010 ; 21 : 765-778.
 
5) Hayakawa M, Sawamura A, Gando S, et al : Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase. Surgery 2011 ; 149 : 221-230.
PubMed
6) 岡本好司 救急外科領域のDIC. In : 鈴木重統, 後藤信哉, 松野一彦 (編) 止血・血栓ハンドブック. 西村書店 : 2015 : pp91-98.
 
7) 社団法人日本麻酔科学会, 有限責任中間法人日本輸血・細胞治療学会. 危機的出血への対応ガイドライン (改訂版). http://www.anesth.or.jp/guide/pdf/kikitekiGL2.pdf
 
8) Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis : a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012 ; 114 (2) : 261-274.
PubMed
9) 藤井輝久, 齋藤誠司. 外傷性難治性出血に対するフィブリノゲン製剤及び遺伝子組み換え型活性化第VII因子製剤による止血治療. 臨床血液 2014 ; 55 : 234-238.
 
10) Stainsby D, et al : Management of massive blood loss : a template guideline. Br J Anaesth 2000 ; 85 : 487-491.
PubMed
11) Martinowitz U, et al. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding : a report by the Israeli Multidisciplinary taskforce. J Thromb Haemost 2005 ; 3 : 640-648.
 
12) Gruen RL, Brohi K, Schreiber M, et al. Haemorrhage control in severely injured patients. Lancet 2012 ; 22 : 380 (9847) : 1099-1108.
 
13) Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients : two parallel randomized, placebo-controlled, double-blindclinical trials. J Trauma Injury Infect Crit Care 2005 ; 59 : 8-18.
 
14) Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial : efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma Injury Infect Crit Care 2010 ; 69 : 489-500.
 
15) Bain J, Lewis D, Bernard A, et al.Implementation of an off-label recombinant factor VIIa protocol for patients with critical bleeding at an academic medical center. J Thromb Thrombolysis 2014 ; 38 (4) : 447-52.
PubMed
16) The CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) : a randomised, placebo-controlled trial. Lancet 2010 ; 376 : 23-32.
 
17) The CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients : an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011 ; 377 : 1096-1101.
PubMed
18) Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1 : 1 : 1 vs a 1 : 1 : 2 Ratio and Mortality in Patients With Severe Trauma The PROPPR Randomized Clinical Trial. JAMA 2015 ; 313 (5) : 471-482.
 
19) 厚生労働省. 輸血療法の実施に関する指針及び血液製剤の使用指針 日本赤十字社 血液事業本部 平成17年9月 (平成19年7月一部改正) (平成19年11月一部改正) (平成21年2月一部改正) (平成24年3月一部改正)
 
20) CapA, Hunt BJ. The pathogenesis of traumatic coagulopathy. Anaesthesia. 2015 ; 70 Suppl 1 : 96-101, e32-34.
 
21) Gando S, Otomo Y. Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care. 2015 ; 19 : 72.
 
22) Mann KG, Freeman K ; TACTIC Investigator list. TACTIC : Trans-Agency Consortium for Trauma-Induced Coagulopathy. J Thromb Haemost. 2015 ; 13 Suppl 1 : S63-71.
 
P.175 掲載の参考文献
1) 丸藤哲. 侵襲と生体反応. In : 日本救急医学会監修, 日本救急医学会専門医認定委員会編. 救急診療指針. 東京 : へるす出版, 2011 : 593-602.
 
2) 丸藤哲, 澤村淳, 早川峰司, 他. 感染性・非感染性生体侵襲と生体反応. 救急医学 2011 ; 35 : 747-752.
 
3) 丸藤哲, 和田剛志. 神経内分泌・自律神経反応と炎症反応. Thrombosis Medicine 2014 ; 4 : 5-14.
Medical*Online
4) 丸藤哲, 和田剛志. 神経内分泌・自律神経反応と凝固線溶反応. Thrombosis Medicine 2014 ; 4 : 15-19.
Medical*Online
5) Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013 ; 3 : 34-45.
 
6) 丸藤哲. 大量出血と臓器不全. In : 外須美夫編. 大量出血. 東京 : 真興交易医書出版部, 2006 : 54-64.
 
7) Waxman K. Shock : ischemia, reperfusion, and inflammation. New Horiz 1996 ; 4 : 153-160.
PubMed
8) Chrousos GP. The hypothalamic-pituitary- adrenal axis and immune-mediated inflammation. N Engl J Med 1995 ; 332 : 1351-1362.
PubMed
9) Esmon CT. Innate immunity and coagulation. J Thromb Haemost 2011 ; 9 (suppl.1) : 182-188.
 
10) Tracy KJ. Reflex control of immunity. Nat Rev Immunol 2009 ; 9 : 418-428.
 
11) Olofsson PS, Rosas-Ballina M, Levine YA, et al. Rethinking inflammation : neural circuits in the regulation of immunity. Immunol Rev 2012 ; 248 : 184-204.
 
12) Wallen NH, Goodall AH, Li N, et al. Activation of haemostasis by exercise, mental stress and adrenaline : effects on platelet sensitivity to thrombin and thrombin generation. Clin Sci 1999 ; 97 : 27-35.
PubMed
13) van der Poll T, Levi M, Dentener M, et al. Epinephrine exerts anticoagulant effects during human endotoxemia. J Exp Med 1997 ; 185 : 1143-1148.
PubMed
14) Rosnoblet C, Vischer UM, Gerard RD, et al. Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells. Arterioscler Thromb Vasc Biol 1999 ; 19 : 1796-1803.
 
15) Parmer RJ, Mahata M, Mahata S, et al. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. J Biol Chem 1997 ; 272 : 1976-1982.
 
16) Wang Y, Hand AR, Wang YH, et al. Functional and morphologic evidence of the presence of tissue plasminogen activator in vascular nerves : implications for a neurologic control of vessel wall fibrinolysis and rigidity. J Neurosci Res 1998 ; 53 : 443-453.
PubMed
17) van Westerloo DJ, Giebelen IA, Meijers JC, et al. Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. J Thromb Haemost 2006 ; 4 : 1997-2002.
PubMed
P.183 掲載の参考文献
1) 国連難民高等弁務官事務所編. ストレスへの対処. In : 緊急対応ハンドブック 日本語版. UNHCR日本・韓国地域事務所, 2000 : 352-359.
 
2) Mittleman MA, Maclure M, Sherwood JB et al : Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Investigators. Circulation 1995 ; 92 : 1720-1725.
PubMed
3) Kark JD, Goldman S, Epstein L. Iraqi missile attacks on Israel. The association of mortality with a lifethreatening stressor. JAMA 1995 ; 273 : 1208-10.
PubMed
4) Steinberg JS, Arshad A, Kowalski M, et al : Increased incidence of life-threatening ventricular arrhythmias in implantable defibrillator patients after the World Trade Center attack. J Am Coll Cardiol. 2004 ; 44 : 1261-4.
PubMed
5) Brotman DJ, Golden SH, Wittstein IS. The Cardiovascular Toll of Stress. Lancet 2007 ; 370 : 1089-1100.
PubMed
6) Huang JL, Chiou CW, Ting CT, et al : Sudden changes in heart rate variability during the 1999 Taiwan earthquake. Am J Cardiol. 2001 ; 87 : 245-248.
PubMed
7) Jouven X, Empana JP, Schwartz PJ, et al : Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005 ; 352 : 1951-1958.
PubMed
8) Jain D, Shaker SM, Burg M, et al : Effects of mental stress on left ventricular and peripheral vascular performance in patients with coronary artery disease. J Am Coll Cardiol 1998 ; 31 : 1314-1322.
PubMed
9) Yeung AC, Vekshtein VI, Krantz DS, et al : The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 1991 ; 325 : 1551-1556.
PubMed
10) Kario K, Matsuo K, Kobayashi H, et al : Earthquakeinduced potentiation of acute risk factors in hypertensive elderly patients : possible triggering of cardiovascular events after a major earthquake . J Am Coll Cardiol 1997 ; 29 : 926-933.
 
11) Aoki T, Fukumoto Y, Yasuda S, et al. The Great East Japan Earthquake Disaster and cardiovascular diseases. Eur Heart J 2012 ; 33 : 2796-2803.
PubMed
12) Aoki T, Takahashi J, Fukumoto Y, et al. Effect of the Great East Japan Earthquake on cardiovascular diseases--report from the 10 hospitals in the disaster area. Circ J 2013 ; 77 : 490-493.
PubMed
13) Kario K, Matsuo T : Increased incidence of cardiovascular attacks in the epicenter just after the Hanshin-Awaji earthquake. Thromb Haemost 1995 ; 74 : 1207.
PubMed
14) Kario K, Matsuo T, Kayaba K, Soukejima S, Kagamimori S, Shimada K. Earthquake-induced cardiovascular disease and related risk factors in focusing on the Great Hanshin-Awaji Earthquake. J Epidemiol. 1998 ; 8 : 131-139.
PubMed
15) Matsuo T, Suzuki S, Kodama K, et al. Hemostatic activation and cardiac events after the 1995 Hanshin-Awaji earthquake. Int J Hematol. 1998 ; 67 : 123-129.
PubMed
16) Watanabe H, Kodama M, Tanabe N, et al. Impact of earthquakes on risk for pulmonary embolism. Int J Cardiol 2008 ; 129 (1) : 152-154.
PubMed
17) 呂彩子, 谷藤隆信, 景山則正, 他. 院外発症の肺動脈塞栓症による突然死51例の病理形態学的検討. 脈管学 2003 ; 43 : 627-632.
 
18) 榛沢和彦, 岡本竹司, 名村理, 他. 震災被災者のDVT陽性率は避難所環境を示す : 東日本大震災におけるDVT検査結果. 日外会誌 2014 ; 115 臨時増刊: 70.
 
19) Sakuma M, Konno Y, Shirato K. Increasing mortality from pulmonary embolism in Japan, 1951-2000. Circ J 2002 ; 66 : 1144-1149.
PubMed
20) Nakamura M, Fujioka H, Yamada N, et al. Clinical characteristics of acute pulmonary thromboembolism in Japan : results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol 2001 ; 24 : 132-138.
PubMed
21) Miniati M, Prediletto R, Formichi B, et al. Accuracy of clinical assessment in the diagnosis of pulmonary embolism. Am Respir Crit Care Med 1999 ; 159 : 864-871.
PubMed
22) Sugimura K, Sakuma M, Shirato K. Potential risk factors and incidence of pulmonary thromboembolism in Japan : results from an overview of mailed questionnaires and a matched case-control study. Circ J 2006 ; 70 : 542-547.
 
23) Konstantinides S. Acute Pulmonary Embolism. N Engl J Med 359 : 2804-2813, 2008.
PubMed
24) Richiman P B, Loutfi H, Lester S T, et al. Electrocardiographic findings in emergency department patients with pulmonary embolism. J Emerg Med 27 : 121-126, 2004.
 
25) Worsley D F, Alavi A, Aronchick J M, et al. Chest radiographic findings in patients with acute pulmonary embolism : observations from the PIOPED Study. Radiology 189 : 133-136, 1993.
PubMed
26) Wells P S, Anderson D R, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging : management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med 2001 ; 135 : 98-107.
 
27) Kearon C, Ginsberg JS, Douketis J, et al. An evaluation of D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med 2006 ; 144 : 812-821.
PubMed
28) Dalen JE, Alpert JD. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975 ; 17 : 259-269.
 
29) Stein PD, Kayali F, Olson RE. Trends in the use of diagnostic imaging in patients hospitalized with acute pulmonary embolism. Am J Cardiol 2004 ; 93 : 1316-1317.
PubMed
30) Hogg K, Brown G, Dunning J, et al : Diagnosis of pulmonary embolism with CT pulmonary angiography : a systemic review. Emerg Med J 2006 ; 23 : 172-178.
 
31) Ota M, Nakamura M, Yamada N, et al. Prognostic significance of early diagnosis in acute pulmonarythromboembolism with circulatory failure. Heart Vessels 2002 ; 17 : 7-11.
PubMed

書評

最近チェックした商品履歴

Loading...